CoChat

The solute carrier transporters and the brain: Physiological and pharmacological implications

Open access
Hu, Chengliang, Tao, Lei, Cao, Xizhi, Chen, Ligong · 2020 · Asian Journal of Pharmaceutical Sciences
Cited by 157

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Solute carriers (SLCs) are the largest family of transmembrane transporters that determine the exchange of various substances, including nutrients, ions, metabolites, and drugs across biological membranes. To date, the presence of about 287 SLC genes have been identified in the brain, among which mutations or the resultant dysfunctions of 71 SLC genes have been reported to be correlated with human brain disorders. Although increasing interest in SLCs have focused on drug development, SLCs are currently still under-explored as drug targets, especially in the brain. We summarize the main substrates and functions of SLCs that are expressed in the brain, with an emphasis on selected SLCs that are important physiologically, pathologically, and pharmacologically in the blood-brain barrier, astrocytes, and neurons. Evidence suggests that a fraction of SLCs are regulated along with the occurrences of brain disorders, among which epilepsy, neurodegenerative diseases, and autism are representative. Given the review of SLCs involved in the onset and procession of brain disorders, we hope these SLCs will be screened as promising drug targets to improve drug delivery to the brain.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajps.2019.09.002

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 125

  1. Hediger, 2013, The ABCs of membrane transporters in health and disease (SLC series): introduction, Mol Aspects Med, 34, 95, 10.1016/j.mam.2012.12.009 · DOI · Paper page
  2. Zhang, 2019, The SLC transporter in nutrient and metabolic sensing, regulation, and drug development, J Mol Cell Biol., 11, 1, 10.1093/jmcb/mjy052 · DOI · Paper page
  3. Cesar-Razquin, 2015, A call for systematic research on solute carriers, Cell, 162, 478, 10.1016/j.cell.2015.07.022 · DOI · Paper page
  4. Song, 2019, Organic cation transporter 3 (Oct3) is a distinct catecholamines clearance route in adipocytes mediating the beiging of white adipose tissue, PLoS Biol, 17, 10.1371/journal.pbio.2006571 · DOI
  5. Hall, 2019, l-Type amino acid transporter 1 activity of 1,2,3-triazolyl analogs of l-histidine and l-tryptophan, Bioorg Med Chem Lett;, 10.1016/j.bmcl.2019.06.033 · DOI
  6. Guan, 2018, Elevated na/h exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas, J Exp Clin Cancer Res, 37, 255, 10.1186/s13046-018-0923-z · DOI
  7. Li, 2018, Subcellular drug distribution: mechanisms and roles in drug efficacy, toxicity, resistance, and targeted delivery, Drug Metab Rev, 50, 430, 10.1080/03602532.2018.1512614 · DOI
  8. LeVine, 2016, Allosteric mechanisms of molecular machines at the membrane: transport by sodium-coupled symporters, Chem Rev, 116, 6552, 10.1021/acs.chemrev.5b00627 · DOI
  9. Cocucci, 2017, Role of passive diffusion, transporters, and membrane trafficking-mediated processes in cellular drug transport, Clin Pharmacol Ther, 101, 121, 10.1002/cpt.545 · DOI
  10. Hossain, 2019, General and specific interactions of the phospholipid bilayer with P-type ATPases, Biophys Rev, 11, 353, 10.1007/s12551-019-00533-2 · DOI
  11. Drew, 2016, Shared molecular mechanisms of membrane transporters, Annu Rev Biochem, 85, 543, 10.1146/annurev-biochem-060815-014520 · DOI · Paper page
  12. Takahashi, 2015, Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease, Cell Mol Life Sci, 72, 3489, 10.1007/s00018-015-1937-8 · DOI · Paper page
  13. Perland, 2017, Classification systems of secondary active transporters, Trends Pharmacol Sci, 38, 305, 10.1016/j.tips.2016.11.008 · DOI · Paper page
  14. Counillon, 2016, Na(+)/H(+) antiporter (NHE1) and lactate/H(+) symporters (MCTs) in pH homeostasis and cancer metabolism, Biochim Biophys Acta, 1863, 2465, 10.1016/j.bbamcr.2016.02.018 · DOI
  15. Rask-Andersen, 2013, Solute carriers as drug targets: current use, clinical trials and prospective, Mol Aspects Med, 34, 702, 10.1016/j.mam.2012.07.015 · DOI
  16. Brzica, 2017, Role of transporters in central nervous system drug delivery and blood-brain barrier protection: relevance to treatment of stroke, J Cent Nerv Syst Dis, 9, 10.1177/1179573517693802 · DOI · Paper page
  17. Turkova, 2019, Current advances in studying clinically relevant transporters of the solute carrier (SLC) family by connecting computational modeling and data science, Comput Struct Biotechnol J, 17, 390, 10.1016/j.csbj.2019.03.002 · DOI
  18. Al-Abdulla, 2019, Unraveling 'the cancer genome atlas' information on the role of SLC transporters in anticancer drug uptake, Expert Rev Clin Pharmacol, 12, 329, 10.1080/17512433.2019.1581605 · DOI
  19. Liang, 2015, The physiological role of drug transporters, Protein Cell, 6, 334, 10.1007/s13238-015-0148-2 · DOI
  20. Chen, 2019, Regulation of glucose and lipid metabolism in health and disease, Sci China Life Sci, 62, 1420, 10.1007/s11427-019-1563-3 · DOI · Paper page
  21. Spencer, 2018, Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier, J Neurol Neurosurg Psychiatry, 89, 42, 10.1136/jnnp-2017-316011 · DOI · Paper page
  22. Lee, 2017, Hypoxic-ischaemic encephalopathy and the blood-brain barrier in beonates, Dev Neurosci, 39, 49, 10.1159/000467392 · DOI
  23. Wong, 2019, Review of current strategies for delivering alzheimer's disease drugs across the blood-brain barrier, Int J Mol Sci, 20, E381, 10.3390/ijms20020381 · DOI · Paper page
  24. Dadas, 2019, Breakdown of blood brain barrier as a mechanism of post-traumatic epilepsy, Neurobiol Dis, 123, 20, 10.1016/j.nbd.2018.06.022 · DOI · Paper page
  25. Nalecz, 2017, Solute carriers in the blood-brain barier: safety in abundance, Neurochem Res, 42, 795, 10.1007/s11064-016-2030-x · DOI
  26. Puris, 2019, Mechanistic study on the use of the l-type amino acid transporter 1 for brain intracellular delivery of ketoprofen via prodrug: a novel approach supporting the development of prodrugs for intracellular targets, Mol Pharm;, 16, 3261, 10.1021/acs.molpharmaceut.9b00502 · DOI
  27. Abdullahi, 2018, Functional expression of organic anion transporting polypeptide 1a4 is regulated by transforming growth factor-beta/activin receptor-like kinase 1 signaling at the blood-brain barrier, Mol Pharmacol, 94, 1321, 10.1124/mol.118.112912 · DOI
  28. Kou, 2018, Recent advances in drug delivery via the organic cation/carnitine transporter 2 (OCTN2/SLC22A5), Expert Opin Ther Targets, 22, 715, 10.1080/14728222.2018.1502273 · DOI · Paper page
  29. Ferreira, 2017, l-carnitine and acetyl-l-carnitine roles and neuroprotection in developing brain, Neurochem Res, 42, 1661, 10.1007/s11064-017-2288-7 · DOI · Paper page
  30. Napolitano, 2009, Carnitine conjugate of nipecotic acid: a new example of dual prodrug, Molecules, 14, 3268, 10.3390/molecules14093268 · doi:10.3390/molecules14093268
  31. Kou, 2018, l-Carnitine-conjugated nanoparticles to promote permeation across blood-brain barrier and to target glioma cells for drug delivery via the novel organic cation/carnitine transporter OCTN2, Artif Cells Nanomed Biotechnol, 46, 1605
  32. Ronaldson, 2013, Targeted drug delivery to treat pain and cerebral hypoxia, Pharmacol Rev, 65, 291, 10.1124/pr.112.005991 · DOI
  33. Ronaldson, 2011, Inflammatory pain signals an increase in functional expression of organic anion transporting polypeptide 1a4 at the blood-brain barrier, J Pharmacol Exp Ther, 336, 827, 10.1124/jpet.110.174151 · DOI
  34. Ho, 2012, Expression profiling of solute carrier gene families at the blood-CSF barrier, Front Pharmacol, 3, 154, 10.3389/fphar.2012.00154 · DOI · Paper page
  35. Furihata, 2017, Functional expression of organic ion transporters in astrocytes and their potential as a drug target in the treatment of central nervous system diseases, Biol Pharm Bull, 40, 1153, 10.1248/bpb.b17-00076 · DOI
  36. Ashraf, 2014, Functional expression of drug transporters in glial cells: potential role on drug delivery to the CNS, Adv Pharmacol, 71, 45, 10.1016/bs.apha.2014.06.010 · DOI
  37. Duan, 2010, Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3, J Pharmacol Exp Ther, 335, 743, 10.1124/jpet.110.170142 · DOI · Paper page
  38. Takahashi, 2015, Restored glial glutamate transporter EAAT2 function as a potential therapeutic approach for alzheimer's disease, J Exp Med, 212, 319, 10.1084/jem.20140413 · DOI · Paper page
  39. Pajarillo, 2019, The role of astrocytic glutamate transporters GLT-1 and glast in neurological disorders: potential targets for neurotherapeutics, Neuropharmacology, 165
  40. Sery, 2015, GLAST but not least–distribution, function, genetics and epigenetics of l-glutamate transport in brain–focus on GLAST/EAAT1, Neurochem Res, 40, 2461, 10.1007/s11064-015-1605-2 · DOI
  41. Zhang, 2018, Vesicular glutamate transporter isoforms: the essential players in the somatosensory systems, Prog Neurobiol, 171, 72, 10.1016/j.pneurobio.2018.09.006 · DOI
  42. Zander, 2010, Synaptic and vesicular coexistence of vglut and vgat in selected excitatory and inhibitory synapses, J Neurosci, 30, 7634, 10.1523/JNEUROSCI.0141-10.2010 · DOI · Paper page
  43. Tordera, 2007, Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1), Eur J Neurosci, 25, 281, 10.1111/j.1460-9568.2006.05259.x · DOI · Paper page
  44. Janickova, 2017, Vesicular acetylcholine transporter (VAChT) over-expression induces major modifications of striatal cholinergic interneuron morphology and function, J Neurochem, 142, 857, 10.1111/jnc.14105 · DOI
  45. Padua-Reis, 2017, Reduced vesicular acetylcholine transporter favors antidepressant behaviors and modulates serotonin and dopamine in female mouse brain, Behav Brain Res, 330, 127, 10.1016/j.bbr.2017.04.049 · DOI
  46. Pramod, 2013, SLC6 transporters: structure, function, regulation, disease association and therapeutics, Mol Aspects Med, 34, 197, 10.1016/j.mam.2012.07.002 · DOI · Paper page
  47. Rudnick, 2014, The SLC6 transporters: perspectives on structure, functions, regulation, and models for transporter dysfunction, Pflugers Arch, 466, 25, 10.1007/s00424-013-1410-1 · DOI · Paper page
  48. Salatino-Oliveira, 2018, The dopamine transporter role in psychiatric phenotypes, Am J Med Genet B Neuropsychiatr Genet, 177, 211, 10.1002/ajmg.b.32578 · DOI
  49. Efimova, 2016, Dopamine transporter mutant animals: a translational perspective, J Neurogenet, 30, 5, 10.3109/01677063.2016.1144751 · DOI
  50. Traiffort, 2013, The choline transporter-like family SLC44: properties and roles in human diseases, Mol Aspects Med, 34, 646, 10.1016/j.mam.2012.10.011 · DOI
  51. Wang, 2019, Glucose transporter 1 critically controls microglial activation through facilitating glycolysis, Mol Neurodegener, 14, 2, 10.1186/s13024-019-0305-9 · DOI · Paper page
  52. Castellotti, 2019, Screening of SLC2A1 in a large cohort of patients suspected for Glut1 deficiency syndrome: identification of novel variants and associated phenotypes, J Neurol, 266, 1439, 10.1007/s00415-019-09280-6 · DOI
  53. Espinoza-Rojo, 2010, Glucose transporters regulation on ischemic brain: possible role as therapeutic target, Cent Nerv Syst Agents Med Chem, 10, 317, 10.2174/187152410793429755 · doi:10.2174/187152410793429755
  54. Koch, 2019, The glucose transporter type 1 (Glut1) syndromes, Epilepsy Behav, 91, 90, 10.1016/j.yebeh.2018.06.010 · DOI
  55. Sonnay, 2018, Astrocytic and neuronal oxidative metabolism are coupled to the rate of glutamate-glutamine cycle in the tree shrew visual cortex, Glia, 66, 477, 10.1002/glia.23259 · DOI · Paper page
  56. Dienel, 2019, Does shuttling of glycogen-derived lactate from astrocytes to neurons take place during neurotransmission and memory consolidation?, J Neurosci Res, 97, 863, 10.1002/jnr.24387 · DOI · Paper page
  57. Broer, 2001, Transfer of glutamine between astrocytes and neurons, J Neurochem, 77, 705, 10.1046/j.1471-4159.2001.00322.x · DOI · Paper page
  58. Leke, 2016, The glutamine transporters and their role in the glutamate/GABA-glutamine cycle, Adv Neurobiol, 13, 223, 10.1007/978-3-319-45096-4_8 · DOI
  59. Jenstad, 2013, The amino acid transporters of the glutamate/GABA-glutamine cycle and their impact on insulin and glucagon secretion, Front Endocrinol (Lausanne), 4, 199, 10.3389/fendo.2013.00199 · DOI
  60. Gliddon, 2009, Cellular distribution of the neutral amino acid transporter subtype ASCT2 in mouse brain, J Neurochem, 108, 372, 10.1111/j.1471-4159.2008.05767.x · DOI · Paper page
  61. Omote, 2016, Structure, function, and drug interactions of neurotransmitter transporters in the postgenomic era, Annu Rev Pharmacol Toxicol, 56, 385, 10.1146/annurev-pharmtox-010814-124816 · DOI
  62. Gasnier, 2004, The SLC32 transporter, a key protein for the synaptic release of inhibitory amino acids, Pflugers Arch, 447, 756, 10.1007/s00424-003-1091-2 · DOI
  63. Lawal, 2013, SLC18: vesicular neurotransmitter transporters for monoamines and acetylcholine, Mol Aspects Med, 34, 360, 10.1016/j.mam.2012.07.005 · DOI · Paper page
  64. Eiden, 2004, The vesicular amine transporter family (SLC18): amine/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine, Pflugers Arch, 447, 636, 10.1007/s00424-003-1100-5 · DOI · Paper page
  65. Morris, 2017, SLC and abc transporters: expression, localization, and species differences at the blood-brain and the blood-cerebrospinal fluid barriers, AAPS J, 19, 1317, 10.1208/s12248-017-0110-8 · DOI · Paper page
  66. Abdullahi, 2017, Functional expression of P-glycoprotein and organic anion transporting polypeptides at the blood-brain barrier: understanding transport mechanisms for improved CNS drug delivery?, AAPS J, 19, 931, 10.1208/s12248-017-0081-9 · DOI · Paper page
  67. Billington, 2019, Interindividual and regional variability in drug transporter abundance at the human blood-brain barrier measured by quantitative targeted proteomics, Clin Pharmacol Ther, 106, 228, 10.1002/cpt.1373 · DOI
  68. Meszaros, 2018, Niosomes decorated with dual ligands targeting brain endothelial transporters increase cargo penetration across the blood-brain barrier, Eur J Pharm Sci, 123, 228, 10.1016/j.ejps.2018.07.042 · DOI · Paper page
  69. Nigam, 2015, What do drug transporters really do?, Nat Rev Drug Discov, 14, 29, 10.1038/nrd4461 · DOI · Paper page
  70. Lei, 2018, Crystal structure of arginine-bound lysosomal transporter SLC38A9 in the cytosol-open state, Nat Struct Mol Biol, 25, 522, 10.1038/s41594-018-0072-2 · DOI · Paper page
  71. Patching, 2017, Glucose transporters at the blood-brain barrier: function, regulation and gateways for drug delivery, Mol Neurobiol, 54, 1046, 10.1007/s12035-015-9672-6 · DOI · Paper page
  72. Spiciarich, 2019, Global health and epilepsy: update and future directions, Curr Neurol Neurosci Rep, 19, 30, 10.1007/s11910-019-0947-6 · DOI
  73. Loscher, 2013, Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments, Neuropharmacology, 69, 62, 10.1016/j.neuropharm.2012.05.045 · DOI · Paper page
  74. Moore, 2017, Seizing control of KCC2: a new therapeutic target for epilepsy, Trends Neurosci, 40, 555, 10.1016/j.tins.2017.06.008 · DOI
  75. Lykke, 2016, The search for NKCC1-selective drugs for the treatment of epilepsy: structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A, Epilepsy Behav., 59, 42, 10.1016/j.yebeh.2016.03.021 · DOI
  76. Gharaylou, 2019, A preliminary study evaluating the safety and efficacy of bumetanide, an NKCC1 inhibitor, in patients with drug-resistant epilepsy, CNS Drugs, 33, 283, 10.1007/s40263-019-00607-5 · DOI
  77. Eid, 2016, The glutamate-glutamine cycle in epilepsy, Adv Neurobiol, 13, 351, 10.1007/978-3-319-45096-4_14 · DOI
  78. Stergachis, 2019, Recurrent SLC1A2 variants cause epilepsy via a dominant negative mechanism, Ann Neurol, 85, 921, 10.1002/ana.25477 · DOI · Paper page
  79. Zhang, 2019, SLC1A2 mediates refractory temporal lobe epilepsy with an initial precipitating injury by targeting the glutamatergic synapse pathway, IUBMB Life, 71, 213, 10.1002/iub.1956 · DOI
  80. Mattison, 2018, SLC6A1 variants identified in epilepsy patients reduce gamma-aminobutyric acid transport, Epilepsia, 59, e135, 10.1111/epi.14531 · DOI
  81. Dikow, 2014, 3p25.3 microdeletion of GABA transporters SLC6A1 and SLC6A11 results in intellectual disability, epilepsy and stereotypic behavior, Am J Med Genet A, 164a, 3061, 10.1002/ajmg.a.36761 · DOI · Paper page
  82. Hardies, 2015, Recessive mutations in SLC13A5 result in a loss of citrate transport and cause neonatal epilepsy, developmental delay and teeth hypoplasia, Brain, 138, 3238, 10.1093/brain/awv263 · DOI
  83. Thevenon, 2014, Mutations in SLC13A5 cause autosomal-recessive epileptic encephalopathy with seizure onset in the first days of life, Am J Hum Genet, 95, 113, 10.1016/j.ajhg.2014.06.006 · DOI
  84. Weeke, 2017, Punctate white matter lesions in full-term infants with neonatal seizures associated with SLC13A5 mutations, Eur J Paediatr Neurol., 21, 396, 10.1016/j.ejpn.2016.11.002 · DOI
  85. Bhutia, 2017, Plasma membrane Na(+)-coupled citrate transporter (SLC13A5) and neonatal epileptic encephalopathy, Molecules, 22, 378, 10.3390/molecules22030378 · DOI
  86. Pajor, 2014, Sodium-coupled dicarboxylate and citrate transporters from the SLC13 family, Pflugers Arch, 466, 119, 10.1007/s00424-013-1369-y · DOI · Paper page
  87. Bainbridge, 2017, Analyses of SLC13A5-epilepsy patients reveal perturbations of TCA cycle, Mol Genet Metab, 121, 314, 10.1016/j.ymgme.2017.06.009 · DOI
  88. Liang, 2019, Salivary biological biomarkers for Alzheimer's disease, Arch Oral Biol, 105, 5, 10.1016/j.archoralbio.2019.06.004 · DOI
  89. Liu, 2008, Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease, FEBS Lett, 582, 359, 10.1016/j.febslet.2007.12.035 · DOI · Paper page
  90. Piert, 1996, Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET, J Nucl Med, 37, 201
  91. Shah, 2012, The role of glucose transporters in brain disease: diabetes and Alzheimer's disease, Int J Mol Sci, 13, 12629, 10.3390/ijms131012629 · DOI · Paper page
  92. Hooijmans, 2007, Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice, Brain Res, 1181, 93, 10.1016/j.brainres.2007.08.063 · DOI
  93. Kim, 2017, Peripheral brain-derived neurotrophic factor levels in Alzheimer's disease and mild cognitive impairment: a comprehensive systematic review and meta-analysis, Mol Neurobiol, 54, 7297, 10.1007/s12035-016-0192-9 · DOI
  94. Butterfield, 2003, The glutamatergic system and Alzheimer's disease: therapeutic implications, CNS Drugs, 17, 641, 10.2165/00023210-200317090-00004 · DOI · Paper page
  95. Woltjer, 2010, Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in Alzheimer disease, J Neuropathol Exp Neurol, 69, 667, 10.1097/NEN.0b013e3181e24adb · DOI · Paper page
  96. Abdul, 2009, Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling, J Neurosci, 29, 12957, 10.1523/JNEUROSCI.1064-09.2009 · DOI · Paper page
  97. Kalia, 2015, Parkinson's disease, Lancet, 386, 896, 10.1016/S0140-6736(14)61393-3 · DOI · Paper page
  98. Stoessl, 2012, Neuroimaging in parkinson's disease: from pathology to diagnosis, Parkinsonism Relat Disord, 18, S55, 10.1016/S1353-8020(11)70019-0 · DOI
  99. Fu, 2019, Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson's disease induced presynaptic alterations, Neuroimage Clin, 23, 10.1016/j.nicl.2019.101856 · DOI
  100. McHugh, 2015, The structure and function of the dopamine transporter and its role in CNS diseases, Vitam Horm, 98, 339, 10.1016/bs.vh.2014.12.009 · DOI
  101. Ikeda, 2019, Dopamine transporter imaging in Parkinson disease: progressive changes and therapeutic modification after anti-parkinsonian medications, Intern Med., 58, 1665, 10.2169/internalmedicine.2489-18 · DOI
  102. Takahashi, 2019, Quantifying the severity of Parkinson disease by use of dopaminergic neuroimaging, AJR Am J Roentgenol, 1
  103. Singh, 2018, Insights into the structure, function, and ligand discovery of the large neutral amino acid transporter 1, LAT1, Int J Mol Sci, 19, E1278, 10.3390/ijms19051278 · DOI · Paper page
  104. Tarlungeanu, 2016, Impaired amino acid transport at the blood brain barrier is a cause of autism spectrum disorder, Cell, 167, 10.1016/j.cell.2016.11.013 · DOI · Paper page
  105. Liu, 2017, Single nucleotide polymorphisms in SLC19A1 and SLC25A9 are associated with childhood autism spectrum disorder in the chinese HAN population, J Mol Neurosci, 62, 262, 10.1007/s12031-017-0929-6 · doi:10.1007/s12031-017-0929-6
  106. Maekawa, 2015, Investigation of the fatty acid transporter-encoding genes SLC27A3 and SLC27A4 in autism, Sci Rep, 5, 16239, 10.1038/srep16239 · DOI
  107. Abrahamsen, 2013, Allosteric modulation of an excitatory amino acid transporter: the subtype-selective inhibitor UCPH-101 exerts sustained inhibition of EAAT1 through an intramonomeric site in the trimerization domain, J Neurosci, 33, 1068, 10.1523/JNEUROSCI.3396-12.2013 · DOI
  108. Borden, 1994, Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1, Eur J Pharmacol, 269, 219, 10.1016/0922-4106(94)90089-2 · DOI · Paper page
  109. Lowe, 2009, The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter, Bioorg Med Chem Lett, 19, 2974, 10.1016/j.bmcl.2009.04.035 · DOI
  110. Anderson, 2017, Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial, Lancet Psychiatry, 4, 595, 10.1016/S2215-0366(17)30236-5 · DOI · Paper page
  111. Rodrigues, 2017, Tetrabenazine versus deutetrabenazine for Huntington's disease: twins or distant cousins?, Mov Disord Clin Pract, 4, 582, 10.1002/mdc3.12483 · DOI
  112. Tashima, 2015, Intriguing possibilities and beneficial aspects of transporter-conscious drug design, Bioorg Med Chem, 23, 4119, 10.1016/j.bmc.2015.06.022 · DOI
  113. Thiele, 2018, Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug, Bioorg Med Chem Lett, 28, 2856, 10.1016/j.bmcl.2018.07.030 · DOI
  114. Bhunia, 2017, Large amino acid transporter 1 selective liposomes of l-DOPA functionalized amphiphile for combating glioblastoma, Mol Pharm, 14, 3834, 10.1021/acs.molpharmaceut.7b00569 · DOI
  115. Yu, 2019, Gabapentin increases expression of delta subunit-containing gabaa receptors, EBioMedicine, 42, 203, 10.1016/j.ebiom.2019.03.008 · DOI
  116. Panebianco, 2018, Gabapentin add-on treatment for drug-resistant focal epilepsy, Cochrane Database Syst Rev, 10
  117. Dickens, 2013, Transport of gabapentin by LAT1 (SLC7A5), Biochem Pharmacol, 85, 1672, 10.1016/j.bcp.2013.03.022 · DOI
  118. Kim, 2017, Hallmarks of treatment aspects: Parkinson's disease throughout centuries including L-dopa, Int Rev Neurobiol, 132, 295, 10.1016/bs.irn.2017.01.006 · DOI
  119. Ostrom, 2018, CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015, Neuro Oncol, 20, iv1, 10.1093/neuonc/noy131 · DOI · Paper page
  120. Mooney, 2019, Current approaches and challenges in the molecular therapeutic targeting of glioblastoma, World Neurosurg, 129, 90, 10.1016/j.wneu.2019.05.205 · DOI
  121. Bai, 2017, Structural biology of solute carrier (SLC) membrane transport proteins, Mol Membr Biol, 34, 1, 10.1080/09687688.2018.1448123 · DOI · Paper page
  122. Chiduza, 2019, LAT1 (SLC7A5) and CD98hc (SLC3A2) complex dynamics revealed by single-particle cryo-EM, Acta Crystallogr D Struct Biol, 75, 660, 10.1107/S2059798319009094 · DOI
  123. Lee, 2019, Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc, Nat Struct Mol Biol, 26, 510, 10.1038/s41594-019-0237-7 · DOI · Paper page
  124. Geier, 2013, Structure-based ligand discovery for the large-neutral amino acid transporter 1, LAT-1, Proc Natl Acad Sci USA, 110, 5480, 10.1073/pnas.1218165110 · DOI · Paper page
  125. Wittwer, 2013, Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling, J Med Chem, 56, 781, 10.1021/jm301302s · DOI · Paper page

Cited by

See all 157

Metadata

Authors
Hu, C., Tao, L., Cao, X., & Chen, L.
Venue
Asian Journal of Pharmaceutical Sciences
Publisher
Elsevier BV
Published
2020-03
Volume
15
Issue
2
Pages
131-144
ISSN
1818-0876 (ISSN-L)
OpenAlex
W2984225800
Cited by
157
References
17
FWCI
5.99
Type
journal article
Language
en
Open access
diamond
Licence
Funders
  • Ministry of Science and Technology of the People's Republic of China
  • National Natural Science Foundation of China

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The solute carrier transporters and the brain: Physiological and pharmacological implications. https://app.cochat.ai/papers/10.1016/j.ajps.2019.09.002
The paper
Hu, C., Tao, L., Cao, X., & Chen, L. (2020). The solute carrier transporters and the brain: Physiological and pharmacological implications. Asian Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.ajps.2019.09.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.